| 叶山东.基于循证证据的糖尿病肾脏病药物治疗进展[J].中国临床保健杂志,2024,27(5):582-585. |
| 基于循证证据的糖尿病肾脏病药物治疗进展 |
| Progress in drug treatment of diabetic kidney disease based on evidence-based evidence |
| 投稿时间：2024-08-20 |
| DOI：10.3969/J.issn.1672-6790.2024.05.002 |
| 中文关键词: 糖尿病肾脏病 药理作用分子作用机制 循证医学 肾疾病 心血管疾病 |
| 英文关键词: Diabetic nephropathies Molecular mechanisms of pharmacological action Evidence-based medicine Kidney diseases Cardiovascular diseases〖FL |
| 基金项目: |
|
| 摘要点击次数: 358 |
| 全文下载次数: 281 |
| 中文摘要: |
| 糖尿病肾脏病(DKD)是糖尿病的重要慢性并发症,是目前导致终末期肾脏病的首要原因。大量临床研究已证实,血管紧张素转换酶抑制剂和血管紧张素受体拮抗剂对DKD有明确的保护作用。最近有不少大样本多中心随机对照研究显示,一些药物如胰高糖素样肽-1受体激动剂、钠-葡萄糖共转运蛋白2抑制剂和选择性醛固酮受体拮抗剂等对DKD患者有明确的肾脏保护作用,进而降低或逆转蛋白尿,显著延缓肾功能的恶化,改善其预后。该文阐述了这些药物的临床应用与肾脏保护机制。 |
| 英文摘要: |
| Diabetic kidney disease (DKD) is an important chronic complication of diabetes mellitus,and it is currently the single leading cause of end-stage kidney disease.Numerous previous clinical studies have confirmed that angiotensin-converting enzyme inhibition and angiotensin-receptor-Ⅱ antagonism have a clear protective effect on DKD and have been widely used in the clinic.Recently,many large multi-center randomized controlled studies showed that some drugs such as GLP-1 receptor agonists,SGLT-2 inhibitors and selective aldosterone receptor antagonists have clear reno-protective effects in DKD patients,thus reducing or reversing proteinuria and significantly delaying the deterioration of renal function and improving their prognosis.This article describes the clinical applications and renoprotective mechanisms of these drugs. |
|
查看全文
|
| 关闭 |